Actively Recruiting
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
Led by University Hospital, Toulouse · Updated on 2023-09-21
60
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.
CONDITIONS
Official Title
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with an early stage of non small cell lung cancer
- Indication of surgical resection
- Patient able to understand and give his consent
- Patient affiliated to the health insurance
You will not qualify if you...
- Patient with another cancer in the last 5 years
- Patient with an allergy to the contrast medium
- Patient under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Julien MAZIERES
Toulouse, France, 31059
Actively Recruiting
Research Team
J
Julien MAZIERES, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here